Analyzing Envista (NYSE:NVST) and GlucoTrack (NASDAQ:GCTK)

Envista (NYSE:NVST) and GlucoTrack (NASDAQ:GCTK) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.

Earnings and Valuation

This table compares Envista and GlucoTrack”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envista	$2.72 billion	1.61	$47.00 million	$0.28	95.84
GlucoTrack	N/A	N/A	-$19.39 million	($55.51)	-0.01

Envista has higher revenue and earnings than GlucoTrack. GlucoTrack is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Envista and GlucoTrack’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Envista	1.73%	6.54%	3.60%
GlucoTrack	N/A	-324.84%	-178.16%

Institutional & Insider Ownership

10.9% of GlucoTrack shares are held by institutional investors. 1.0% of Envista shares are held by insiders. Comparatively, 2.2% of GlucoTrack shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Envista has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, GlucoTrack has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Envista and GlucoTrack, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envista	0	9	7	0	2.44
GlucoTrack	1	0	0	0	1.00

Envista presently has a consensus target price of $27.85, indicating a potential upside of 3.77%. Given Envista’s stronger consensus rating and higher probable upside, equities analysts clearly believe Envista is more favorable than GlucoTrack.

Summary

Envista beats GlucoTrack on 11 of the 13 factors compared between the two stocks.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

About GlucoTrack

GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.